KCNQ1 and systemic sclerosis: On the other hand, CO inhibits Kv7.1 K+ channel conductance, indicating that modulation of HO-1/CO signaling could be targeted as a novel therapeutic target to treat QT-interval prolongation arrhythmias in late phases of SSc.